30-year pharma veteran Rolf Hoffmann, previously senior world government at Amgen and Eli Lilly, joins Semdor Pharma as investor and industrial professional.
Cologne, March twenty ninth, 2021 — Semdor Pharma Group introduced at present that it has added Rolf Hoffmann, a seasoned world pharma government and advisor, to its Board of Administrators, in addition to an investor within the firm. Mr. Hoffmann beforehand served at Amgen as Senior Vice President of Industrial Operations (US) and SVP of Worldwide and Europe, the place he centered on operations, scaling and organizational improvement. Mr. Hoffmann began his pharmaceutical profession at Eli Lilly as a gross sales consultant, progressing shortly to senior positions together with President of Latin America Operations and Common Supervisor in Germany. Since parting from Amgen in 2016, Mr. Hoffmann has served on quite a few boards associated to the pharmaceutical and biotechnical sector, together with STADA (Germany’s largest unbiased Generics/OTC enterprise), Danish Genmab (Europe’s largest Biotech firm) and EUSA Pharma (a European specialty pharmaceutical firm centered on oncology and oncology supportive care), amongst others.
“Semdor Pharma attracted me due to their clear mission of constructing a next-generation European specialty pharmaceutical firm centered on the large downside of bodily and psychological ache and struggling. No different situation takes such a big emotional and monetary toll on European society and Semdor’s purpose for being is evident. No different European platform is ready to supply the market such a broad array of life-enhancing medicines, from conventional ache drugs to the exploding space of medical hashish merchandise. Semdor has a generational alternative and I’m excited to impart my expertise scaling pharma companies as a Board Director and investor”, stated Rolf Hoffmann.
“I’m pleased with the arduous work of each member of the Semdor staff and our mission stays clear: providing European sufferers probably the most revolutionary, highest high quality ache medication and associated merchandise, whether or not conventional ache therapies or medical hashish. We’re in a stronger place than ever to construct Semdor’s platform, together with the Cannamedical model, as a frontrunner within the European medical hashish business” stated David Henn, CEO of Semdor “With over 30 yr of expertise serving to develop pharma platforms in Europe, North America and Latin America, Rolf is an ideal match as an investor and Board Director.”
About Semdor Pharma Group
The formation of Semdor Pharma Group in January 2021 established considered one of Europe’s main pharmaceutical teams specialised in narcotics and medical hashish. Semdor Pharma Group was shaped via the merger of the German narcotics companies market chief PS Group (together with subsidiaries PS Pharma Providers, PB Pharma and PS Advertising & Outsourcing) and Cannamedical Pharma, which is the main unbiased medical hashish model in Germany. Semdor affords European wholesalers, suppliers and pharmacies the broadest array of narcotic medicines (each artificial and pure) and gives key narcotic and medical hashish gamers the broadest number of market-leading product importing, dealing with, packaging and formulation companies. Semdor Pharma generates gross annual gross sales of greater than 60 million euros and employs 180 staff members in Cologne and Meerbusch, Germany.
Press Relations
Leonie Weskott
E-Mail: presse@semdor-group.com
Telephone: +49 (0) 221 9999 6151
